An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Kumar SK, Dispenzieri A, Lacy MQ et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5), 1122–1128 (2014).
  Medline CASGoogle Scholar
• 2. Demo SD, Kirk CJ, Aujay MA et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67(13), 6383–6391 (2007).
  Medline CASGoogle Scholar
• 3. Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 12(5), 431–440 (2011).
  MedlineGoogle Scholar
• 4. Parlati F, Lee SJ, Aujay M et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114(16), 3439–3447 (2009).
  Medline CASGoogle Scholar
• 5. Herndon TM, Deisseroth A, Kaminskas E et al. US Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin. Cancer Res. 19(17), 4559–4563 (2013).
  Medline CASGoogle Scholar
• 6. Stewart AK, Rajkumar SV, Dimopoulos MA et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372(2), 142–152 (2015).
  MedlineGoogle Scholar
• 7. Suzuki K, Ri M, Chou T et al. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: a phase 1 study in Japan. Cancer Sci. 108(3), 461–468 (2017).
  Medline CASGoogle Scholar
• 8. Kastritis E, Roussou M, Gavriatopoulou M et al. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Adv. 3(23), 4095–4103 (2019).
  Medline CASGoogle Scholar
• 9. Dimopoulos MA, Moreau P, Palumbo A et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17(1), 27–38 (2016).
  Medline CASGoogle Scholar
• 10. Berenson JR, Cartmell A, Bessudo A et al. CHAMPION-1: a phase 1/2 study of once weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood 127(26), 3360–3368 (2016).
  Medline CASGoogle Scholar
• 11. Moreau P, Mateos MV, Berenson JR et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 19(7), 953–964 (2018). •• The phase III trial (ARROW study) comparing the efficacy and safety of once-weekly carfilzomib and dexamethasone therapy with twice-weekly carfilzomib and dexamethasone therapy in patients with relapsed and refractory multiple myeloma.
  Medline CASGoogle Scholar
• 12. Takezako N, Shibayama H, Handa H et al. Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (ARROW) and comparison with ENDEAVOR. Int. J. Hematol. 113(2), 219–230 (2021). •• A subgroup analysis focused on the Japanese patients with multiple myeloma enrolled in the ARROW study comparing with ENDEAVOR study.
  Medline CASGoogle Scholar
• 13. Onda Y, Kanda J, Kaneko H et al. Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. Ther. Adv. Hematol. 13, 1–16 (2022). • A retrospective analysis demonstrating the real-world effectiveness and safety of carfilzomib in combination with lenalidomide and dexamethasone and twice-weekly carfilzomib with dexamethasone therapies in Japanese patients.
  Google Scholar
• 14. Terpos E, Zambello R, Leleu X et al. Real-world use and effectiveness of carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma in Europe. Cancers 14(21), 5311 (2022).
  Medline CASGoogle Scholar
• 15. Durie BGM, Harousseau J-L, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 20(9), 1467–1473 (2006).
  Medline CASGoogle Scholar
• 16. Rajkumar SV, Harousseau J-L, Durie B et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18), 4691–4695 (2011).
  Medline CASGoogle Scholar
• 17. Kawasaki A, Murakami H, Chou T, Matsushita M, Kizaki M. Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma. Future Oncol. 18(24), 2661–2674 (2022).
  CASGoogle Scholar
• 18. Kawaji-Kanayama Y, Kobayashi T, Muramatsu A et al. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: the Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. Cancer Rep. 5(2), e1476 (2022).
  CASGoogle Scholar
• 19. Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J. Once-weekly (70 mg/m²) vs twice-weekly (56 mg/m²) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: a post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials. Cancer Med. 9(9), 2989–2996 (2020). • Post hoc crosstrial comparisons demonstrating the efficacy and safety profiles of once-weekly versus twice-weekly dosing schedules using data from three trials of patients with relapsed or refractory multiple myeloma.
  Medline CASGoogle Scholar
• 20. Dimopoulos MA, Moreau P, Iida S et al. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and ARROW trials. Int. J. Hematol. 110(4), 466–473 (2019). • A subgroup analysis focused on the outcomes of Asian patients with multiple myeloma enrolled in the randomized phase III ENDEAVOR and ARROW trials.
  Medline CASGoogle Scholar
• 21. Dimopoulos MA, Niesvizky R, Weisel K et al. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis. Blood Cancer J. 10(3), 35 (2020).
  MedlineGoogle Scholar
• 22. Das A, Dasgupta S, Gong Y et al. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials. Hematol. Oncol. 40(2), 233–242 (2022).
  Medline CASGoogle Scholar
• 23. Giudice MLD, Gozzetti A, Antonioli E et al. Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro-prospective observational study. Eur. J. Haematol. 109(4), 373–380 (2022).
  MedlineGoogle Scholar
• 24. Kawaji-Kanayama Y, Muramatsu A, Sasaki N et al. Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study. Int. J. Hematol. 115(3), 350–362 (2022).
  Medline CASGoogle Scholar
• 25. Lyon AR, Dent S, Stanway S et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur. J. Heart Fail. 22(11), 1945–1960 (2020). • Baseline cardiovascular risk assessment and baseline risk stratification proformas in cancer patients prior to receiving the following cancer therapies, such as anthracycline chemotherapy, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs).
  MedlineGoogle Scholar